MGTX - MeiraGTx Holdings PLC logo

MGTX

MeiraGTx Holdings PLC

MeiraGTx Holdings plc focuses on developing genetic therapies for serious conditions, including ocular and neurodegenerative diseases. Its pipeline features treatments for retinal dystrophies, Parkinson's disease, and xerostomia, alongside riboswitch technology.

βš•οΈ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago β†’$911today

Score Overview

1 Year
Score
Net Growth22.73%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth144.57%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score4.1
Net Growth-96.93%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth422.98%
Rev Trend60%
Revenue Consistencyβ€”
All Time
Scoreβ€”
Net Growth-37.81%
Net Trend43%
Net Income Consistency
Rev Growthβ€”
Rev Trend71%
Revenue Consistency

See the full market ranking β†’

MeiraGTx Holdings PLC fundamental performance

Between 2020 and 2025, revenue grew from $ 15M to $ 81M and net income went from -$ 57M to -$ 114M. Revenue increased in 3 of those 5 years; net income in 2.

MeiraGTx Holdings PLC currently holds a 5-year HDB Score of 4.1 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 12.96β€”
1 Year2025-08-12
$ 8.0261.60%
5 Years2021-08-12
$ 14.22-8.86%
All Time2018-06-08
$ 15.00-13.60%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 81M-$ 114M$ 65M
2024$ 33M-$ 147M$ 103M
2023$ 14M-$ 84M$ 129M
2022$ 15M-$ 129M$ 115M
2021$ 37M-$ 79M$ 137M
2020$ 15M-$ 57M$ 209M
2019$ 13M-$ 54M$ 227M
IPO2018$ 0.00-$ 82M$ 68M

Explore beyond MGTX

You're looking at MeiraGTx Holdings PLC. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies